Videau Manon, Chemali Lotfi, Stucki Cyril, Saavedra-Mitjans Mar, Largana Samuel, Guerin Aurélie, Bonnabry Pascal, Delhauteur Blaise, Van Hees Thierry, Lebel Denis, Bussières Jean-François
is a PharmD candidate with the Faculty of Pharmacy (ISPB), Université Claude Bernard Lyon 1, Lyon, France, and a Research Assistant with the Pharmacy Practice Research Unit, Pharmacy Department, Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec.
is a PharmD candidate with the Faculty of Pharmacy, Université Paris Descartes, and is also a student intern with the Pharmacy Service, Hôpital Necker-Enfants malades, Paris, France.
Can J Hosp Pharm. 2019 Jan-Feb;72(1):7-15. Epub 2018 Feb 28.
Drug shortages represent a complex global problem affecting patients and health care professionals on a daily basis.
To identify, describe, and compare drug shortages in health care facilities in Canada and 4 European countries in early 2018.
A descriptive cross-sectional study was conducted in 1 hospital in each of 5 countries: Canada, France, Belgium, Spain, and Switzerland. Over a 4-week period, shortage data were collected daily by each hospital using a standardized grid and a standard process.
From January 8 to February 2, 2018, there were a total of 84 shortages (median duration 32 days) in the Canadian hospital, 62 shortages (median duration 9 days) in the French hospital, 46 shortages (median duration 37 days) in the Belgian hospital, 28 shortages (median duration 25 days) in the Spanish hospital, and 98 shortages (median duration 68 days) in the Swiss hospital. The number of manufacturers implicated in the shortages was 28 for the Canadian hospital, 30 for the French hospital, 19 for the Belgian hospital, 16 for the Spanish hospital, and 42 for the Swiss hospital. Most of the shortages involved parenteral drugs, with both innovative and generic manufacturers being affected. Most therapeutic classes were affected by shortages to some extent, with the top 3 classes being anti-infective agents (accounting for 21.1% of shortages overall), central nervous system drugs (11.3%), and cardiovascular drugs (8.2%).
Drug shortages occurred almost daily in all of the study hospitals. Across the 5 hospitals, the frequency of shortages varied by a factor of 3, which may imply similar variability at the national level. All stakeholders should work more diligently to prevent and manage drug shortages.
药品短缺是一个复杂的全球性问题，每天都在影响着患者和医护人员。
识别、描述并比较2018年初加拿大和4个欧洲国家医疗机构中的药品短缺情况。
在加拿大、法国、比利时、西班牙和瑞士这5个国家的各1家医院开展了一项描述性横断面研究。在4周的时间里，每家医院每天使用标准化表格和标准流程收集短缺数据。
2018年1月8日至2月2日，加拿大医院共有84起短缺事件（中位持续时间32天），法国医院有62起短缺事件（中位持续时间9天），比利时医院有46起短缺事件（中位持续时间37天），西班牙医院有28起短缺事件（中位持续时间25天），瑞士医院有98起短缺事件（中位持续时间68天）。涉及短缺事件的制造商数量，加拿大医院为28家，法国医院为30家，比利时医院为19家，西班牙医院为16家，瑞士医院为42家。大多数短缺事件涉及注射用药物，创新药和仿制药制造商均受到影响。大多数治疗类别在一定程度上受到短缺的影响，其中排名前三的类别是抗感染药物（占短缺事件总数的21.1%）、中枢神经系统药物（11.3%）和心血管药物（8.2%）。
所有研究医院几乎每天都发生药品短缺事件。在这5家医院中，短缺事件的发生频率相差3倍，这可能意味着在国家层面也存在类似的差异。所有利益相关者应更加努力地预防和管理药品短缺问题。
